Physician profile
Kyle Langr
NPI 1316257827
$3,045.51
in general payments reported to CMS, 2019-2025
15 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $393 · 2021: $615 · 2022: $346 · 2023: $224 · 2024: $327 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $516.09 | 2019-2023 | Dailies |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $491.12 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $402.47 | 2019-2024 | Acuvue |
| Coopervision INC. | $344.10 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $246.81 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $212.95 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $148.70 | 2025 | Vevye |
| Shire North American Group INC | $133.53 | 2019 | |
| Bausch & Lomb Americas INC. | $125.84 | 2025 | Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $124.46 | 2021 | |
| Allergan, INC. | $120.06 | 2022 | |
| Optovue, INC. | $80.47 | 2019 | |
| Glaukos Corporation | $73.12 | 2019 | |
| Optos, INC. | $14.84 | 2022 | |
| Abb Con-Cise Optical Group LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Langr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.